Saturday, July 11, 2026

pharma · Neoplasms,Non-Small Cell Lung Cancer

Tianjin Hemay Pharmaceutical

Tianjin Hemay Pharmaceutical drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
2
Patents
0
Intelligence · Drug Pipeline

Tianjin Hemay Pharmaceutical pipeline

Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Tianjin Hemay Pharmaceutical drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

2 compounds
  1. Development asset linked to Tianjin Hemay Pharmaceutical in public FDA and regional records.

  2. Development asset linked to Tianjin Hemay Pharmaceutical in public FDA and regional records.